Exsure’s Breakthrough in Biotech: A New Era in Cancer Treatment
Bhubaneswar-based biotech startup Exsure has recently raised Rs 3 crore in a seed funding round led by Unicorn India Ventures. This investment marks a significant milestone in Exsure’s journey to revolutionize cancer treatment through its innovative exosomal drug-delivery platform. As the biotech industry continues to grow, Exsure’s advancements could have far-reaching implications for cancer patients worldwide.
Exsure’s Vision for Cancer Treatment
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure aims to reduce the side effects and toxicity of anti-cancer drugs. Their patented exosomal drug-delivery platform targets both cancer and cancer stem cells, potentially minimizing the toxic effects of chemotherapy and reducing the chances of cancer relapse. This innovative approach is designed to improve the quality of life for cancer patients, addressing a critical need in oncology.
Swastika Paul, CSO & Co-founder of Exsure, shared insights from her PhD journey, stating, "During our PhD journey, we witnessed the toxicity of the present-day chemotherapy drugs and how 13% of the in-treatment cancer patients die due to toxicity of the chemotherapy drugs. Exsure is on a mission to reduce the toxicity of the chemotherapy drugs and make them more targeted to the cancerous cells. Our vision is to empower millions of cancer patients around the world and improve their quality of life."
Market Presence and Growth
In the past year, Exsure has made significant strides in its non-clinical study in India, collaborating with a Contract Research Organization (CRO) to complete key milestones. The startup has reported a fivefold growth last fiscal year and is on track to serve over 50 clients with its R&D products, including Exosure, Leucosure, and PlantExosure. These products are gaining traction in the biotech industry, showcasing Exsure’s potential to impact the market significantly.
Exsure’s selection for the OIST Innovation Accelerator program in Japan further underscores its potential for business expansion and clinical trials. In the coming months, the company plans to finish its non-clinical study, strengthen its team, and expand its product marketing and sales on a global scale.
Industry Potential and Challenges
The Indian biotechnology industry is poised for substantial growth, with projections suggesting it could reach $150 billion by 2025 and potentially $270-300 billion by 2030, according to the Indian Brand Equity Foundation (IBEF). Exsure’s innovative approach aligns with this growth trajectory, offering promising solutions for cancer treatment.
However, the path to success in the biotech industry is fraught with challenges. The complexity of drug development, regulatory hurdles, and the need for substantial investment are just a few of the obstacles that startups like Exsure must navigate. The recent funding round led by Unicorn India Ventures provides a crucial boost to Exsure’s mission, enabling it to advance its research and development efforts.
Bhaskar Majumdar, Managing Partner at Unicorn India Ventures, emphasized the importance of Exsure’s work, stating, "The fear of Big C is real not just for the patients but even their families. Exsure with its advancement in scientific tools, technology and cutting edge medical research has built a powerful Exosome based drug that commits to staying at the forefront of advancement in therapeutics science. The funding accelerates Exsure’s mission to deploy solutions at a global level."
The Road Ahead for Exsure
As Exsure continues to innovate and expand, it faces the challenge of scaling its operations while maintaining the quality and efficacy of its treatments. The startup’s focus on team building, securing CDSCO approval, and global expansion will be critical in achieving its long-term goals.
For those interested in the biotech industry, Exsure’s journey offers valuable insights into the challenges and opportunities that startups face. The company’s commitment to improving cancer treatment through cutting-edge technology exemplifies the potential for innovation to transform lives.
Conclusion
Exsure’s recent funding round and its innovative approach to cancer treatment highlight the potential for biotech startups to make a significant impact in the healthcare industry. As the Indian biotechnology sector continues to grow, Exsure’s advancements could pave the way for more effective and targeted cancer therapies, ultimately improving the quality of life for millions of patients worldwide.
For more information about Exsure and its groundbreaking work in biotech, visit Exsure’s website.
